HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...
Grail continues facing significant challenges as its stock plummeted over 45% after its landmark NHS-Galleri trial failed to ...
NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on ...
After the weight-loss drug boom, and with generics closing in, Big Pharma are gearing up for the next game-changer.
Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million Completed Galleri PMA Submission to FDA Shared Topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results